Targeting a key pathway in prostate cancer to improve treatment outcomes
Macrocycle inhibition of beta-catenin mediated transcription in prostate cancer
This study is exploring a new way to treat advanced prostate cancer by testing special compounds that might block a pathway linked to aggressive cancer growth, aiming to find better treatment options for patients who aren't responding well to current therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11094908 on NIH RePORTER |
What this research studies
This research investigates a new approach to treating prostate cancer by focusing on the Wnt/β-catenin signaling pathway, which is often activated in aggressive forms of the disease. The study aims to develop and test novel macrocyclic compounds that can inhibit this pathway, potentially overcoming resistance to current anti-androgen therapies. By utilizing advanced 3D cell culture techniques, researchers will evaluate how these compounds affect prostate cancer cell growth and gene expression. This innovative methodology seeks to provide insights into more effective treatment options for patients with advanced prostate cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with advanced or metastatic prostate cancer, particularly those who have developed resistance to current anti-androgen treatments.
Not a fit: Patients with localized prostate cancer or those who have not yet undergone anti-androgen therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that significantly improve survival rates and quality of life for patients with advanced prostate cancer.
How similar studies have performed: While targeting the Wnt/β-catenin pathway in prostate cancer is a relatively novel approach, similar strategies have shown promise in other cancers, indicating potential for success.
Where this research is happening
New York, United States
- New York University School of Medicine — New York, United States (Active)
Researchers
- Principal investigator: Logan, Susan K. — New York University School of Medicine
- Study coordinator: Logan, Susan K.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.